Survodutide: SYNCHRONIZE-CVOT results disclosure
Boehringer's October update says results from SYNCHRONIZE-CVOT are expected later in 2026. This cardiovascular-safety trial is distinct from already reported SYNCHRONIZE-1/2 weight-loss results and from the newly registered ELEVATE-LIVER cardiac-imaging study.
Boehringer IngelheimDrug catalystsClinical data publicationDate to watch
What matters
Track what the company has actually announced, the study or asset involved, and the evidence needed to confirm the milestone.
- Research candidate, not a live listing. Study completion and public results disclosure are distinct.
Primary evidence
Sponsor expectation: later in 2026 — exact day unconfirmed
Boehringer · October program update and CVOT outlookPublished 2026-10-01
ClinicalTrials.gov · SYNCHRONIZE-CVOTPublished 2026-10-29
ClinicalTrials.gov API · SYNCHRONIZE-CVOTPublished 2026-10-29
Potential outcome market
Will the sponsor publicly disclose the prespecified main SYNCHRONIZE-CVOT cardiovascular-safety analysis by a separately fixed evidence cutoff?
This event is research, not a listed market. A market needs a precise question, resolution rules and liquidity before trading opens.